Oncology/Hematology

Brand Name
Description
Abstral™
(sublingual fentanyl)
Abstral™ is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain
Caphosol®
(Dibasic Sodium Phosphate Monobasic Sodium Phosphate Calcium Chloride )
Caphosol® is indicated for dryness of the mouth and oropharynx (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol® is also indicated as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain.
PecFent® 
(fentanyl citrate nasal spray, solution)
PecFent® is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.
Sancuso®
(granisetron transdermal patch)
SANCUSO transdermal patch is indicated in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult
Brand Name
Description
Halaven®
(eribulin mesilate)
Halaven® is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. It is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease
Lenvima®
(lenvatinib)
Lenvima® is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. It is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy
Brand Name
Description
Brukinsa®
(zanubrutinib)
Brukinsa® is indicated for the treatment of adults with mantle cell lymphoma who have received at least one prior treatment for their cancer.
Diseases
Description
Multicentric
Castleman's Disease
Multicentric Castleman Disease (MCD) is a rare disease that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "systemic" and involves multiple regions of lymph nodes. The signs and symptoms of MCD are often nonspecific, and are mild in some people but serious in others. Symptoms may include enlarged lymph nodes in multiple regions, fever, weight loss, nausea, rash, and/or an enlarged large liver and spleen. For more information on available treatment options, please contact us on [email protected]
Neuroblastoma
Neuroblastoma is a tumor that develops from neuroblasts (immature nerve tissue) in an infant or child, usually before the age of 5. It most often develops in infancy and may be diagnosed in the 1st month of life. The tumor most often develops in the adrenal gland, but may develop in the neck, chest, or spinal cord. It is considered an aggressive tumor because it often spreads to other parts of the body. In most cases, it has spread by the time it is diagnosed. A Neuroblastoma can cause a variety of signs and symptoms, including a lump where the tumor is growing, bone pain, diarrhea, and various neurological symptoms. For more information on available treatment options, please contact us on [email protected]
  • THE MEDICAL INFORMATION AVAILABLE ON THIS WEBSITE IS FOR GENERAL INFORMATION ONLY AND IS NOT A SUBSTITUTE OR REPLACEMENT FOR A MEDICAL CONSULTATION, NOR DOES IT CONSTITUTE ADVICE, RECOMMENDATION OR SUGGESTION FOR SELF-PRESCRIPTION OR SELF-MEDICATION.
  • USERS SHOULD NOT USE THIS INFORMATION TO ASSESS, DIAGNOSE OR TREAT ANY MEDICAL COMPLAINT AND PATIENTS MUST SEEK PROFESSIONAL ADVICE FROM A QUALIFIED PHYSICIAN BEFORE TAKING ANY ACTION IN RESPECT OF INFORMATION PROVIDED ON THIS WEBSITE.
  • THE AVAILABILITY OF PRODUCTS MARKETED BY NEWBRIDGE MAY VARY BY COUNTRY AND YOU MUST CHECK WITH YOUR LOCAL REGULATORY AUTHORITIES FOR RELEVANT INFORMATION OR VARIATIONS.
  • THIS WEBSITE CONTAINS INFORMATION ABOUT MEDICINAL PRODUCTS REGISTERED REGIONALLY NOT ALL OF THE PRODUCTS AND/OR INDICATIONS THAT ARE MENTIONED ON THE WEBSITE OF NEWBRIDGE ARE AVAILABLE IN ALL THE MARKETS, AS SOME OF THESE PRODUCTS ARE CURRENTLY UNDER REGISTRATION ACROSS THE MENA REGION AND ARE SUBJECT TO APPROVAL ACCORDING TO LOCAL LAWS AND REGULATIONS, AND/OR MAY BE MARKETED BY COMPANIES OTHER THAN NEWBRIDGE PHARMACEUTICALS
  • PLEASE REFER TO YOUR LOCAL NEWBRIDGE PHARMACEUTICAL SATELLITE OFFICE TO ADVISE ON THE AVAILABILITY OF THESE PRODUCTS AND REFER TO COUNTRY SPECIFIC LOCALLY APPROVED PRESCRIBING INFORMATION FOR MORE DETAILS ON THE PRODUCT AND INDICATIONS IN YOUR COUNTRY. THE INFORMATION INCLUDED IN THIS WEBSITE IS NOT INTENDED TO CONSTITUTE PROMOTION IN ANY MANNER OF ANY OF THE DRUGS REFERENCED.
  • THE INFORMATION POSTED ON THIS WEBSITE IS PROVIDED FOR GENERAL INFORMATION PURPOSES ONLY. WHILST NEWBRIDGE PHARMACEUTICALS WILL MAKE EVERY REASONABLE EFFORT TO INCLUDE ACCURATE AND UP-TO-DATE INFORMATION, WE SHALL NOT HOWEVER BE LIABLE IN ANY WAY FOR ERRORS OR OMISSIONS IN THE CONTENTS OF THIS WEBSITE. ALL INFORMATION IS PROVIDED "AS IS". CONSEQUENTLY, THE INFORMATION SHOULD BE CAREFULLY EVALUATED BY SITE VISITORS AND NEWBRIDGE PHARMACEUTICALS DOES NOT PROVIDE ANY WARRANTIES ABOUT COMPLETENESS OR ACCURACY OF THE INFORMATION ON THIS WEBSITE OR ITS POSSIBLE USES.
  • THIS WEBSITE CONTAINS LINKS TO THIRD PARTIES' PAGES OR WEBSITES AND NEWBRIDGE PHARMACEUTICALS MAKES NO REPRESENTATION, NOR DOES IT HAVE ANY RESPONSIBILITY IN RELATION TO ANY MATERIAL OR INFORMATION YOU OBTAIN FROM ANY SUCH PAGES OR WEBSITES.